المؤلفون: Rainer Hamacher, Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Lukas Kessler, Phyllis F. Cheung, Sebastian Bauer, Ken Herrmann, Hans-Ulrich Schildhaus, Jens T. Siveke, Wolfgang P. Fendler

المصدر: PET Clinics. 18:361-367

مصطلحات موضوعية: Radiation, Radiology, Nuclear Medicine and imaging, General Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9057ae4d25b36068df1c7e179257b087Test
https://doi.org/10.1016/j.cpet.2023.02.008Test

المؤلفون: Lennart Schardt, Moritz Kaths, Sebastian Bauer

المصدر: Wiener klinisches Magazin. 26:68-73

مصطلحات موضوعية: General Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4e70971aec3dadc37558cea4496a3140Test
https://doi.org/10.1007/s00740-023-00488-xTest

المؤلفون: Nashita Patel, Shibani Pokras, Jane Ferma, Vicky Casey, Fil Manuguid, Ken Culver, Sebastian Bauer

المصدر: Future Oncology.

مصطلحات موضوعية: Cancer Research, Oncology, General Medicine

الوصف: Aim: Describing the treatment patterns, outcomes by line of treatment (LOT), and healthcare resource utilization (HCRU) in patients with metastatic synovial sarcoma (mSS). Patients & methods: In this descriptive, non-interventional, retrospective cohort study, physicians from five European countries reported on patients with recent pharmacological treatment for mSS. Results: Among 296 patients with mSS, 86.1, 38.9 and 8.4% received 1 LOT (1L), 2 LOTs (2L) and 3+ LOTs (L3+), respectively. Common regimens were doxorubicin/ifosfamide-based (37.4%) for 1L and trabectedin-based for 2L (29.7%). For 1L, median time to next treatment was 13.1 and 6.0 months for living and deceased patients, respectively. Median OS was 22.0, 6.0 and 4.9 months in all patients, 2L and 3L, respectively. HCRU data showed median one inpatient hospital admission, 3 days in hospital and four outpatient visits yearly. Conclusion: This large-scale study documents high unmet needs in patients previously treated for mSS and for more effective therapies.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::acd7dea9eaf3459795d4209b010f8711Test
https://doi.org/10.2217/fon-2022-1005Test

المؤلفون: Abbas Agaimy, Alena Skalova, Alessandro Franchi, Rana Alshagroud, Anthony J Gill, Robert Stoehr, Daniel Baumhoer, Sebastian Bauer

مصطلحات موضوعية: Pathology and Forensic Medicine, Histology, General Medicine

الوصف: n/a

العلاقة: url:https://www.openaccessrepository.it/communities/itmirrorTest; https://www.openaccessrepository.it/record/46778Test

الإتاحة: https://doi.org/10.1111/his.14053Test
https://www.openaccessrepository.it/record/46778Test

المؤلفون: Julia Würtemberger, Tim Ripperger, Christian Vokuhl, Sebastian Bauer, Irene Teichert-von Lüttichau, Eva Wardelmann, Charlotte M Niemeyer, Christian P. Kratz, Brigitte Schlegelberger, Simone Hettmer

المصدر: European Journal of Medical Genetics. 66:104718

مصطلحات موضوعية: Medizin, Genetics, General Medicine, Genetics (clinical)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c4fef5dc073b7f87ab8f7438b19898eTest
https://doi.org/10.1016/j.ejmg.2023.104718Test

المؤلفون: Anton G. Henssen, Beate Timmermann, Gustaf Ljungman, Bernarda Kazanowska, Marc Münter, Thomas Klingebiel, Felix Niggli, Jörg Fuchs, Ewa Koscielniak, Ruth Ladenstein, Christian Vokuhl, Steffan Loff, Sebastian Bauer, Monika Scheer

المصدر: Journal of Cancer Research and Clinical Oncology

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Medicin och hälsovetenskap, Cancer Research, medicine.medical_specialty, Multivariate analysis, Adolescent, medicine.medical_treatment, Original Article – Clinical Oncology, Medizin, Medical and Health Sciences, Time, Synovial sarcoma, Sarcoma, Synovial, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Adjuvant therapy, Humans, Adjuvant therapies, Chemotherapy, Medicine, Child, Hematology, Radiotherapy, Pediatric sarcoma, business.industry, Soft tissue sarcoma, Infant, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Radiation therapy, 030104 developmental biology, Chemotherapy, Adjuvant, Child, Preschool, 030220 oncology & carcinogenesis, Soft-tissue sarcoma, Female, Radiotherapy, Adjuvant, business, Adjuvant

الوصف: Background The benefit of adjuvant therapy in synovial sarcoma (SS) treatment is under debate. Long-term follow-up data are missing. Methods SS patients treated in the consecutive trials CWS-81, CWS-86, CWS-91, CWS-96, CWS-2002-P, and the SoTiSaR-registry till 2013 were analyzed. Results Median age of 185 patients was 13.9 years (0.1–56)—with median follow-up of 7.4 years for 163 survivors. Most tumors (76%) were located in extremities. Size was 10 cm in 13 (7%) (13 missing). In 84 (45%) tumors, first excision was complete (R0 corresponding to IRS-I-group) and in 101 (55%) marginal (R1 corresponding to IRS-II-group). In a subsequent surgical intervention during chemotherapy, R0-status was accomplished in 23 additional IRS-II-group patients with secondary surgery. Radiotherapy was administered to 135 (73%), thereof 62 with R0-status and 67 R1-status (6 missing information). Adjuvant chemotherapy was administered to all but six patients. 5-year event-free (EFS) and overall survival (OS) was 82.9% ± 5.7 (95%CI) and 92.5% ± 3.9. Local and metastatic relapse-free survival was 91.3% ± 4.3 and 92.3% ± 4.1 at 5 years, respectively. In the multivariate analysis, tumor size and no chemotherapy were independently associated with EFS. Size and site were associated with OS. In a detailed analysis of local and metastatic events, tumor size was associated with an independent risk for developing metastases. No independent factor for suffering local recurrence could be identified. Discussion Omission of chemotherapy in a non-stratified way seems not justified. Size governs survival due to high linear association with risk of suffering metastatic recurrence in a granular classification.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8667be913f8f684176e4c3fcb454cb32Test
https://doi.org/10.1007/s00432-021-03614-6Test

المؤلفون: Che-Jui Lee, Elodie Modave, Bram Boeckx, Bernd Kasper, Steinar Aamdal, Michael G. Leahy, Piotr Rutkowski, Sebastian Bauer, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski

المصدر: International Journal of Molecular Sciences; Volume 23; Issue 10; Pages: 5689

مصطلحات موضوعية: Biochemistry & Molecular Biology, Chemistry, Multidisciplinary, molecular profiling, Medizin, immunological characterization, Soft Tissue Neoplasms, CREATE, alveolar soft part sarcoma, Catalysis, Translocation, Genetic, Inorganic Chemistry, PATHWAY, Crizotinib, Tumor Microenvironment, Humans, tumor microenvironment, Physical and Theoretical Chemistry, Molecular Biology, Spectroscopy, COPY NUMBER ANALYSIS, crizotinib, Science & Technology, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Organic Chemistry, PLATFORM, General Medicine, TUMORS, Computer Science Applications, TFE3, Chemistry, gene alteration, Sarcoma, Alveolar Soft Part, ALK, Physical Sciences, MET, Life Sciences & Biomedicine

الوصف: Alveolar soft part sarcoma (ASPS) is a rare subtype of soft tissue sarcoma characterized by an unbalanced translocation, resulting in ASPSCR1-TFE3 fusion that transcriptionally upregulates MET expression. The European Organization for Research and Treatment of Cancer (EORTC) 90101 "CREATE" phase II trial evaluated the MET inhibitor crizotinib in ASPS patients, achieving only limited antitumor activity. We performed a comprehensive molecular analysis of ASPS tissue samples collected in this trial to identify potential biomarkers correlating with treatment outcome. A tissue microarray containing 47 ASPS cases was used for the characterization of the tumor microenvironment using multiplex immunofluorescence. DNA isolated from 34 available tumor samples was analyzed to detect recurrent gene copy number alterations (CNAs) and mutations by low-coverage whole-genome sequencing and whole-exome sequencing. Pathway enrichment analysis was used to identify diseased-associated pathways in ASPS sarcomagenesis. Kaplan-Meier estimates, Cox regression, and the Fisher's exact test were used to correlate histopathological and molecular findings with clinical data related to crizotinib treatment, aiming to identify potential factors associated with patient outcome. Tumor microenvironment characterization showed the presence of PD-L1 and CTLA-4 in 10 and 2 tumors, respectively, and the absence of PD-1 in all specimens. Apart from CD68, other immunological markers were rarely expressed, suggesting a low level of tumor-infiltrating lymphocytes in ASPS. By CNA analysis, we detected a number of broad and focal alterations. The most common alteration was the loss of chromosomal region 1p36.32 in 44% of cases. The loss of chromosomal regions 1p36.32, 1p33, 1p22.2, and 8p was associated with shorter progression-free survival. Using whole-exome sequencing, 13 cancer-associated genes were found to be mutated in at least three cases. Pathway enrichment analysis identified genetic alterations in NOTCH signaling, chromatin organization, and SUMOylation pathways. NOTCH4 intracellular domain dysregulation was associated with poor outcome, while inactivation of the beta-catenin/TCF complex correlated with improved outcome in patients receiving crizotinib. ASPS is characterized by molecular heterogeneity. We identify genetic aberrations potentially predictive of treatment outcome during crizotinib therapy and provide additional insights into the biology of ASPS, paving the way to improve treatment approaches for this extremely rare malignancy. ispartof: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES vol:23 issue:10 ispartof: location:Switzerland status: published

وصف الملف: Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eb60c2ddb7d6d2ed6175baa6ca566ceTest
https://lirias.kuleuven.be/handle/20.500.12942/696638Test

المؤلفون: Lazaros Lazaridis, Teresa Schmidt, Christoph Oster, Tobias Blau, Daniela Pierscianek, Jens T. Siveke, Sebastian Bauer, Hans-Ulrich Schildhaus, Ulrich Sure, Kathy Keyvani, Christoph Kleinschnitz, Martin Stuschke, Ken Herrmann, Cornelius Deuschl, Björn Scheffler, Sied Kebir, Martin Glas

المصدر: Journal of cancer research and clinical oncology.

مصطلحات موضوعية: Cancer Research, Oncology, Medizin, General Medicine

الوصف: Purpose When brain cancer relapses, treatment options are scarce. The use of molecularly matched targeted therapies may provide a feasible and efficacious way to treat individual patients based on the molecular tumor profile. Since little information is available on this strategy in neuro-oncology, we retrospectively analyzed the clinical course of 41 patients who underwent advanced molecular testing at disease relapse. Methods We performed Sanger sequencing, targeted next generation sequencing, and immunohistochemistry for analysis of potential targets, including programmed death ligand 1, cyclin D1, phosphorylated mechanistic target of rapamycin, telomerase reverse transcriptase promoter mutation, cyclin-dependent kinase inhibitor 2A/B deletion, or BRAF-V600E mutation. In selected patients, whole exome sequencing was conducted. Results The investigation included 41 patients, of whom 32 had isocitrate dehydrogenase (IDH) wildtype glioblastoma. Molecular analysis revealed actionable targets in 31 of 41 tested patients and 18 patients were treated accordingly (matched therapy group). Twenty-three patients received molecularly unmatched empiric treatment (unmatched therapy group). In both groups, 16 patients were diagnosed with recurrent IDH wildtype glioblastoma. The number of severe adverse events was comparable between the therapy groups. Regarding the IDH wildtype glioblastoma patients, median progression-free survival (mPFS) and median overall survival (mOS) were longer in the matched therapy group (mPFS: 3.8 versus 2.0 months, p = 0.0057; mOS: 13.0 versus 4.3 months, p = 0.0357). Conclusion These encouraging data provide a rationale for molecularly matched targeted therapy in glioma patients. For further validation, future study designs need to additionally consider the prevalence and persistence of actionable molecular alterations in patient tissue.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff5dbdda468a580a74499237e661415Test
https://pubmed.ncbi.nlm.nih.gov/35953681Test

المؤلفون: Silvia Stacchiotti, Hans Roland Dürr, Inga-Marie Schaefer, Klaus Woertler, Rick Haas, Annalisa Trama, Augusto Caraceni, Jyoti Bajpai, Giacomo Giulio Baldi, Nicholas Bernthal, Jean-Yves Blay, Kjetil Boye, Javier-Martin Broto, Wei-Wu Tom Chen, Paolo Angelo Dei Tos, Jayesh Desai, Stephan Emhofer, Mikael Eriksson, Alessandro Gronchi, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, John Healey, Antoine Italiano, Robin L. Jones, Akira Kawai, Andreas Leithner, Herbert Loong, Eric Mascard, Carlo Morosi, Nadine Otten, Emanuela Palmerini, Shreyaskumar R. Patel, Peter Reichardt, Brian Rubin, Piotr Rutkowski, Claudia Sangalli, Kathrin Schuster, Beatrice M. Seddon, Morena Shkcodra, Eric L. Staals, William Tap, Matt van de Rijn, Kirsten van Langevelde, Filip M.M. Vanhoenacker, Andrew Wagner, Lisette Wiltink, Sydney Stern, Michiel Van de Sande, Sebastian Bauer

المصدر: Cancer treatment reviews

مصطلحات موضوعية: Oncology, Medizin, Radiology, Nuclear Medicine and imaging, Human medicine, General Medicine

الوصف: Weitere Nicht-UDE Autoren sind nicht mit aufgeführt. enosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A global consensus meeting was organized in June 2022, involving experts from several disciplines and patient representatives from SPAGN to define the best evidence-based practice for the optimal approach to TGCT and generate the recommendations presented herein.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4452557d2c4acfbc535a3daae309445Test
https://doi.org/10.1016/j.ctrv.2022.102491Test

المؤلفون: André Palmini, Jonathan P. Miller, Giorgio LoRusso, Milan Brázdil, Asim Shahid, Rebecca O'Dwyer, Hajo M. Hamer, Bernhard J. Steinhoff, Kiyohito Terada, Hans Holthausen, Nuria Lacuey, Shi Hui Lim, Américo Ceiki Sakamoto, Hans O. Lüders, Antonio Gil-Nagel, Walter van Emde Boas, Michael Devereaux, Gerhard Kurlemann, Thomas Bast, K Krakow, Susanne Schubert-Bast, Selim R. Benbadis, Susanne Knake, Adriana Bermeo-Ovalle, Stefan Beyenburg, Günter Krämer, Patrick Landazuri, Norman Delanty, Soheyl Noachtar, Jayanti Mani, Luisa V. Londoño, Bettina Schmitz, Andres M. Kanner, Felix Rosenow, Naoki Akamatsu, Jan Rémi, Sebastian Bauer, Christoph Baumgartner, Matthew C. Walker, Alireza Bozorgi, Lauren Ghanma, Stefano Francione, Mar Carreño, John S. Duncan, Naiara García Losarcos, Philippe Kahane, Manuel Toledo, Guadalupe Fernandez-Baca Vaca, Shirin Jamal Omidi, Jun T. Park, Philipp S. Reif, Riki Matsumoto, Stjepana Kovac, Adam Strzelczyk, Peter Widdess-Walsh, Stephan Schuele, C. Ákos Szabó, Giri Kalamangalam, Andrew Bleasel, Nitin Tandon

المصدر: Seizure. 78:31-37

مصطلحات موضوعية: Epilepsy, Concordance, Headline, General Medicine, medicine.disease, Patient preference, Terminology, 03 medical and health sciences, 0302 clinical medicine, Neurology, Practice Guidelines as Topic, Epilepsy syndromes, medicine, Etiology, Humans, Ictal, Neurology (clinical), Psychology, Societies, Medical, 030217 neurology & neurosurgery, Cognitive psychology

الوصف: Over the last few decades the ILAE classifications for seizures and epilepsies (ILAE-EC) have been updated repeatedly to reflect the substantial progress that has been made in diagnosis and understanding of the etiology of epilepsies and seizures and to correct some of the shortcomings of the terminology used by the original taxonomy from the 1980s. However, these proposals have not been universally accepted or used in routine clinical practice. During the same period, a separate classification known as the "Four-dimensional epilepsy classification" (4D-EC) was developed which includes a seizure classification based exclusively on ictal symptomatology, which has been tested and adapted over the years. The extensive arguments for and against these two classification systems made in the past have mainly focused on the shortcomings of each system, presuming that they are incompatible. As a further more detailed discussion of the differences seemed relatively unproductive, we here review and assess the concordance between these two approaches that has evolved over time, to consider whether a classification incorporating the best aspects of the two approaches is feasible. To facilitate further discussion in this direction we outline a concrete proposal showing how such a compromise could be accomplished, the "Integrated Epilepsy Classification". This consists of five categories derived to different degrees from both of the classification systems: 1) a "Headline" summarizing localization and etiology for the less specialized users, 2) "Seizure type(s)", 3) "Epilepsy type" (focal, generalized or unknown allowing to add the epilepsy syndrome if available), 4) "Etiology", and 5) "Comorbidities & patient preferences".

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa27baa3603c34bb3b0008f73c6bef4Test
https://doi.org/10.1016/j.seizure.2020.02.018Test